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ABSTRACT
Cytokines are thought to play an important role in the pathophysiology of graft-versus-host disease (GVHD).
To study the relationship between cytokines and GVHD, we obtained peripheral blood mononuclear cells
(MNCs) from 21 patients with hematologic malignancies and their HLA-identical sibling donors before and
sequentially after hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning. The MNCs
were cultured for 72 hours either alone or in mixed lymphocyte cultures with irradiated MNCs of recipient,
donor, or HLA-mismatched third-party origin. The gene expression of interleukin (IL)–2, IL-4, IL-10, IL-18,
tumor necrosis factor , and transforming growth factor  in each culture was then measured by real-time
quantitative reverse transcriptase-polymerase chain reaction. The composition of the responder MNCs dif-
fered between patients and donors and changed after HCT, with a possible influence on the results. Early after
transplantation (day 14), the IL-10 messenger RNA (mRNA) level in response to recipient or donor antigens
was higher in patients who did not develop clinically significant acute GVHD when compared with the level in
patients who subsequently developed acute GVHD grades II to IV (P  .005 and P  .004, respectively). The
IL-10 mRNA level on day 14 was highly correlated with the pretransplantation mRNA level of the recipient
MNCs but not with the level of the donor MNCs; this suggests that the IL-10 mRNA detected on day 14
originated from responder cells of recipient origin. A higher IL-10 mRNA level was found in MNCs obtained
before transplantation from recipients whose disease progressed or relapsed after the transplantation when
compared with the level in patients whose disease did not progress or relapse (P  .03). In conclusion, a high
IL-10 gene expression in the recipient MNCs may be related to a reduced incidence of acute GVHD grades
II to IV and a reduced graft-versus-tumor effect after HCT with nonmyeloablative conditioning.
© 2006 American Society for Blood and Marrow Transplantation
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vNTRODUCTION
Reduced-intensity or nonmyeloablative condi-
ioning regimens in hematopoietic cell transplantation
HCT) have extended the use of this potentially cur-
tive treatment to patients who, because of age or
omorbidities, were previously ineligible for HCT.
raft-versus-host disease (GVHD) remains one of the i
8ajor complications associated with this treatment
1,2], and further insight into the pathogenesis of
VHD is therefore important to develop approaches
hat can reduce the incidence of this complication.
he release of inﬂammatory cytokines such as tumor
ecrosis factor (TNF)– has been shown to be in-
olved in the pathophysiology of GVHD [3,4], and
nterleukin (IL)–10 and transforming growth factor
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Cytokine Gene Expression in Hematopoietic Cell Transplantation
BTGF)– have been identiﬁed as important factors in
he control of alloreactivity [5-7].
The role of cytokines in the development of
VHD in the clinical setting has therefore been ex-
lored in different ways. Gene polymorphisms that
nﬂuence the production or effect of several cytokines
ave been related to the clinical outcome [8-10], and
unctional assays that measure cytokine production or
ytokine gene expression in mixed lymphocyte cul-
ures (MLCs) performed before transplantation have
een used to predict clinical events such as acute
VHD [11-13]. After transplantation, the occurrence
f GVHD has been compared with the cytokine levels
n serum or plasma [14-23] or with the cytokine gene
xpression in cells from peripheral blood [22,24-31].
he exact relationship among cytokines, alloreactiv-
ty, and the effect on the overall success of the treat-
ent is, however, not completely elucidated, and only
few studies have included patients who have under-
one transplantation with nonmyeloablative or re-
uced-intensity conditioning regimens [17,24,32-35].
he results obtained in recipients of myeloablative
onditioning may not be applicable in the nonmy-
loablative setting because of the different patient
opulations treated and the requirement for a po-
ent graft-versus-tumor (GVT) effect after nonmy-
loablative conditioning.
In this study, real-time quantitative reverse transcrip-
ase-polymerase chain reaction (RT-PCR) was used to
nalyze the gene expression of IL-2, IL-4, IL-10,
L-18, TNF-, and TGF- in peripheral blood
ononuclear cells (MNCs) obtained from donors and
ecipients before and after HLA-identical HCT with
onmyeloablative conditioning. The results suggested
hat a high IL-10 messenger RNA (mRNA) level in
NCs obtained on day 14 and cultured in the
resence of recipient or donor antigens was related to
low incidence of acute GVHD grades II to IV. The
retransplantation IL-10 mRNA level was higher in
atients who experienced relapse than in those who
id not. In conclusion, IL-10 may be related to re-
uced alloreactivity after HCT with nonmyeloablative
onditioning. Although the reduced incidence of acute
VHD is beneﬁcial for the patients, this may be at
he expense of a reduced GVT effect.
ATERIALS AND METHODS
atients and Donors
Twenty-one patients with hematologic malignan-
ies and their HLA-identical sibling donors were in-
luded. The patients, unique patient numbers (UPNs)
28, 633, 636, 645, 650, 656, 662, 669, 682, 688, 692,
94, 708, 715, 723, 733, 741, 760, 766, 780, and 796,
nderwent transplantation between 2000 and 2003 with
eripheral blood stem cells after nonmyeloablative con- l
B & M Titioning consisting of 2 Gy of total body irradiation
ith or without ﬂudarabine 90 mg/m2 combined with
yclosporine and mycophenolate mofetil as posttrans-
lantation immunosuppression [36-38]. The patients,
onors, and volunteers gave written informed consent
efore inclusion, and the local ethics committee ap-
roved the study. Acute and chronic GVHD were
iagnosed and graded according to standard criteria
39]. Patients who survived 80 days were evaluated
or the occurrence of chronic GVHD.
reparation and Storage of MNCs
MNCs were obtained 2 weeks before the start of
onditioning from leukaphereses performed in all the
atients and in 16 of the donors as recently described
40]. The MNCs obtained from the remaining do-
ors, HLA-mismatched volunteers, and patients after
ransplantation were separated from heparinized pe-
ipheral blood samples by gradient centrifugation
Lymphoprep; Axis Shield PoC, Oslo, Norway). The
NCs were cryopreserved in liquid nitrogen in 50%
edium (RPMI 1640 with 100 IU/mL penicillin, 100
g/mL streptomycin, and 2 mmol/L l-glutamine, all
rom Invitrogen, Tåstrup, Denmark), 40% heat-inac-
ivated human serum from male AB donors (ICN
iomedicals, Aurora, OH), and 10% dimethyl sulfox-
de. The patients were scheduled to have blood sam-
les taken on days 7, 14, 21, 28, 42, 56,
90, 120, 180, 270, and 365.
n Vitro Stimulation
The MNCs were thawed, washed twice in me-
ium, and resuspended in medium with 10% human
erum (culture medium). Viable cells were counted by
sing the trypan blue exclusion method. To deﬁne the
ptimal incubation period, 2 experiments of 9 cultures
ontaining 5  104 responder cells and 5  104 HLA-
ismatched stimulator cells irradiated with 50 Gy
rom a cesium 137 source were performed in culture
edium in round-bottomed 96-well microtiter plates.
he cultures were incubated at 37°C in 7.5% carbon
ioxide. Each day, except for day 7, the content of 1
ell was removed and centrifuged, and the cell pellet
as frozen. The gene expression of IL-18 was not
xamined in this experiment. The MNCs obtained
efore transplantation were cultured in duplicate in a
nal volume of 200 L of culture medium in 96-well
lates. The wells contained 5  104 unstimulated
NCs, 5  104 MNCs cultured in the presence of 3
g/mL phytohemagglutinin (PHA), MLC with 5 
04 responder MNCs and 5  104 irradiated HLA-
dentical MNCs (donor versus recipient and vice
ersa), or 5  104 responder MNCs and 5  104
rradiated HLA-mismatched third-party MNCs. The
NCs obtained after transplantation were unstimu-ated, stimulated with PHA, or cultured with irradi-
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5ted donor, recipient, or third-party MNCs. The cul-
ures containing irradiated HLA-mismatched cells or
HA were included as positive controls. All cultures
ere incubated for 72 hours, whereafter the plates
ere centrifuged at 800g for 3 minutes, and 2 75 L
f supernatant was stored at 20°C. The cell pellets
ere stored at 80°C.
esponder Cell Composition
The fractions of CD4 T cells, CD8 T cells, B
ells, natural killer cells, and monocytes present in the
esponder and stimulator cells were determined by
-color ﬂow cytometry on a FACScan ﬂow cytometer
Becton Dickinson Immunocytometry Systems, San
ose, CA) by using monoclonal antibodies obtained
rom Becton Dickinson. The percentages of donor
himerism of CD4 and CD8 T cells were deter-
ined as previously described [38].
L-2 and IL-4 in Culture Supernatants
The content of secreted bioactive IL-2 and IL-4 in
ach well was measured by use of the CTLL-2 cell
ine (American Tissue Culture Collection, Rockville,
D) and the CT.h4S cell line (a generous gift of
.E. Paul, National Institute of Allergy and Infec-
ious Diseases, National Institutes of Health, Be-
hesda, MD), respectively, as described previously
41,42]. The detection limits were 6 pg/mL for the
TLL-2 bioassay and 5 pg/mL for the CT.h4S bio-
ssay.
eneration of Complementary DNA
Messenger RNA was extracted from the frozen
ell pellets by using the Dynabeads mRNA DIRECT
it (Dynal Biotech, Oslo, Norway) according to the
anufacturer’s instructions. A negative sample con-
aining culture medium only was included in each
xtraction. Complementary DNA (cDNA) was gener-
ted in GeneAmp tubes (Applied Biosystems, Foster
ity, CA) in a ﬁnal volume of 20 L by using 2 L of
0 PCR Rxn Buffer (Invitrogen), 2 L of 50
mol/L MgCl2 (Invitrogen), 8 L of deoxyribo-
ucleoside triphosphate mix corresponding to a ﬁnal
oncentration of 2.5 mmol/L (Ultrapure dNTP Set;
mersham Pharmacia Biotech, Piscataway, NJ), 1 L
f murine leukemia virus reverse transcriptase (50
/L; Applied Biosystems), 1 L of ribonuclease in-
ibitor (20 U/L; Applied Biosystems), 1 L of ran-
om hexanucleotides corresponding to a ﬁnal concen-
ration of 0.25 mol/L (DNA Technology, Århus,
enmark), and 5 L of mRNA. Ten microliters of
ineral oil (Applied Biosystems) was added to each
ube, and cDNA was generated by using 30 minutes at
2°C followed by 5 minutes at 99°C. The cDNA was
tored at 80°C. D
0ytokine Gene Expression
Expression of 2-microglobulin, IL-2, IL-4, IL-10,
L-18, TNF-, and TGF- genes was determined by
eal-time quantitative multiplex RT-PCR by using pre-
eveloped TaqMan assay reagents (control and target
its; Applied Biosystems) in a ﬁnal volume of 25 L in
6-well plates obtained from Applied Biosystems, by
sing the TaqMan ABI 7700 and 7900HT Sequence
etection Systems (Applied Biosystems). Each well con-
ained 2.9 L of cDNA, 7.1 L of ribonuclease-free
ater, 12.5 L of Master Mix (Applied Biosystems),
.25 L of primers and probes for 2-microglobulin
labeled with VIC® dye; Applied Biosystems), and 1 of
he 6 cytokine genes (labeled with FAM™ dye; Ap-
lied Biosystems). After initial steps of 2 minutes at
0°C and 10 minutes at 95°C, 50 cycles of 15 seconds
t 95°C followed by 1 minute at 60°C were per-
ormed. Sequence Detection System software version
.0 was used for data analysis. The relative mRNA
evel of the cytokine was calculated as 2Ct, where Ct
s the threshold cycle (Ct) value for 2-microglobulin
inus the Ct value for the cytokine. A threshold was
hosen for each plate so that the Ct values for both
2-microglobulin and for the cytokines were obtained
n the log phase of the PCR reactions. This threshold
as most often close to 0.2. Ct was rounded to the
earest whole ﬁgure. The lower limit of detection in
his assay was arbitrarily set to a Ct of 15, which
orresponds to a 3 105 times lower mRNA level of
he cytokine than of 2-microglobulin. The reason for
his was that Ct values lower than 15 were often
bserved when the Ct value for the cytokine was 40
ycles.
tatistical Methods
Except for the initial longitudinal experiment,
nly data representing the mean of duplicate cultures
ere used. The relative mRNA levels were compared
y using the Friedman test for paired data and the
ruskal-Wallis test for unpaired data. In both cases, the
unn correction for multiple comparisons was used for
he post hoc tests. The Mann-Whitney test was used
o compare the IL-10 mRNA level in cells from pa-
ients with or without acute GVHD or relapse. Non-
arametric correlation (Spearman) was used to corre-
ate continuous data. The data for clinical follow-up
ere last updated on March 17, 2005. Of the study
ohort, 15 patients were followed up with blood sam-
les for a full year, whereas the remaining 6 patients
ere followed up for a median of 120 days (range,
8-180 days). Samples from patients whose disease
rogressed or relapsed were not excluded from the
tudy. A P value 	.05 was considered signiﬁcant.
raphPad Prism version 4 (GraphPad Software, San
iego, CA) was used for all calculations.
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Cytokine Gene Expression in Hematopoietic Cell Transplantation
BESULTS
linical Results
The patient characteristics are listed in Table 1.
ix patients (UPN 636, 656, 662, 688, 715, and 780)
ied a median of 160 days after transplantation (range,
2-659 days), and 6 patients (UPN 650, 682, 688, 708,
15, and 733) experienced progression or relapse at a
edian of 413 days (range, 56-728 days), as previously
escribed [37]. The median follow-up in surviving
atients was 1371 days (range, 762-1826 days). Two
atients developed acute GVHD grade I, 10 patients
eveloped grade II, 1 patient developed grade III, and
patients developed grade IV. Sixteen of the 20 evalu-
ble patients developed limited or extensive chronic
VHD at a median of 216 days after transplantation
range, 100-476 days) [37].
essenger RNA Levels and Protein Secretion
f IL-2 and IL-4
We used 2 different real-time PCR platforms (the
BI 7700 and 7900HT) and found no differences in
he results obtained (data not shown). On the basis of
he initial longitudinal experiment, we concluded that
days (72 hours) of incubation would be optimal for
he study of cytokine gene expression in the HLA-
ismatched MLC (Figure 1). To make the experi-
ents practical and comparable, all the subsequently
erformed cultures were incubated for 72 hours. The
L-2 and IL-4 mRNA levels and the results of IL-2
nd IL-4 measurements in the supernatants were
ompared, and a high degree of correlation was ob-
erved for both cytokines (Spearman r 
 0.78 and r 

.84, respectively; P 	 .0001 in both cases; data not
hown). The simultaneous detection of cytokine
RNA in the cell pellet and bioactive cytokine in the
upernatant occurred in 36% of the cultures for IL-2
nd in 23% for IL-4. In a large proportion of cultures
29% for IL-2 and 66% for IL-4), we were unable to
able 1. Patient Characteristics
Variable Data
ge, y, patient/donor, median (range) 51 (34-63)/52 (36-68)
ex (male/female) 17/4
iagnosis
Non-Hodgkin lymphoma (NHL) 6 (29%)
Chronic lymphocytic leukemia 4 (19%)
Hodgkin disease 2 (10%)
Multiple myeloma 4 (19%)
Myelodysplastic syndrome (MDS) 3 (14%)
NHL and MDS 2 (10%)
ime from diagnosis to transplantation,
mo, median (range) 54 (6-118)
isease status at transplantation
Complete remission 4 (19%)
Partial remission 14 (67%)
Progressive disease 3 (14%)etect either mRNA or cytokine in the supernatant, (
B & M Tnd only in 1% for IL-2 and 2% for IL-4 did we
etect cytokine in the supernatant without detectable
RNA. In the remaining 34% of the cultures for IL-2
nd 9% for IL-4, we detected mRNA without mea-
urable cytokine in the supernatant. In these cultures,
he median mRNA level was 16 and 11 times lower,
espectively, than the level in the cultures in which
L-2 and IL-4 could be detected by the cell lines. We
onclude that for IL-2 and IL-4, there is a relationship
etween the mRNA level and the amount of secreted
rotein. The measurement of IL-2 and IL-4 mRNA
y real-time RT-PCR may be more sensitive than the
etection of cytokine by the CTLL-2 and the CT.h4S
ell lines.
retransplantation Cytokine Gene Expression
n MNCs from Patients and Donors
The pretransplantation responses to the different
timuli were compared with the unstimulated cultures
n the recipient and donor groups (Figure 2). For
L-2, the responses to HLA-identical MNCs were not
ifferent from the unstimulated cultures, but signiﬁ-
ant responses were observed to PHA in the recipients
nd to HLA-mismatched third-party MNCs and PHA
n the donors (Figure 2a). For IL-4 and TNF-, the
esponses to PHA could be distinguished from the
nstimulated cultures (Figure 2b and c), whereas for
L-10 and TGF-, this was observed only in the
onor MNCs (Figure 2d and e). The mRNA level of
L-18 was signiﬁcantly lower in the PHA-stimulated
ultures than in the unstimulated cultures (Figure 2f).
hese ﬁndings indicate that for the cytokines exam-
ned in this study, the analysis of cytokine mRNA in
n HLA-identical MLC performed with cells obtained
efore transplantation from patients and donors does
ot yield additional information compared with the
nalysis of the unstimulated cells. That this is not due
o a general unresponsiveness is illustrated by the
esponses to third-party cells and to PHA. When
omparing results in patients and donors, we observed
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5igher mRNA levels of IL-10 and TGF- in the
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re 2d and e), and in the cultures stimulated with
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nd 21 donors (D). The responder MNCs were unstimulated or st
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he results were compared within the recipient and donor cohorts
ruskal-Wallis test. The Dunn multiple comparison correction waLA-mismatched MNCs, the IL-2 mRNA level was u
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Cytokine Gene Expression in Hematopoietic Cell Transplantation
Bonors in the cytokine mRNA levels of the unstimu-
ated cells and in the ability to respond to third-party
ntigens could represent functional differences of the
esponding cells or differences in the composition of
he responder MNCs. We examined the composition
f the responder MNCs and found a lower percentage
f CD4 T cells in the recipient MNCs (median,
8%; range, 0.3%-33%) than in the donor MNCs
median, 44%; range, 27%-58%; P 	 .001; Kruskal-
allis test with the Dunn correction for multiple
omparisons). No differences could be demonstrated
or the other cell types investigated (data not shown).
o analyze whether the CD4 T-cell number inﬂu-
nced the results shown in Figure 2, we examined the
RNA level of IL-2 per CD4 T cell, because this
ytokine is primarily produced by activated CD4 T
ells. In the wells containing third-party stimulator
ells, we found no difference in the level of IL-2 per
D4 T cell when responder cells of recipient and
onor origin were compared (P 
 .25; Mann-Whit-
ey test), a ﬁnding that was in contrast to the obser-
ation in Figure 2a. In conclusion, the cell composi-
ion is a factor that is likely to confound the results of
ytokine mRNA analysis of unfractionated MNCs.
ytokine Gene Expression after Transplantation
After transplantation, stimulation with PHA in-
reased the mRNA levels of IL-2, IL-4, IL-10, and
NF- and decreased the IL-18 mRNA level (data not
hown). Stimulation with HLA-mismatched MNCs in-
reased the IL-2 mRNA level and slightly decreased
he IL-10 mRNA level (data not shown). The cytokine
RNA levels in the cultures stimulated with recipient
r donor MNCs resembled the unstimulated cultures
TNF-, TGF-, and IL-4; Figure 3) or showed mi-
or differences (IL-18 and IL-2; Figure 3a). It is
nteresting to note that the IL-10 mRNA level early
fter transplantation was higher in the cultures stim-
lated with recipient or donor MNCs when compared
ith the unstimulated cultures (P 
 .0006 and P 

006, respectively, on day 14; Wilcoxon signed rank
est), thus indicating that in contrast to the pretrans-
lantation experiments, we were able to detect signif-
cant responses to irradiated HLA-identical MNCs
fter transplantation (Figure 3b).
We have previously found that patients with a
igh donor CD8T-cell count on day14 had a high
isk of development of acute GVHD grades II to IV
38]. The mRNA levels of the immunoregulatory cy-
okines IL-10 and of TGF- were therefore further
xamined with relation to the development of acute
VHD (Figure 4). Whereas the mRNA level of
GF- in patients who developed acute GVHD
rades 0 or I and grades II to IV did not depend on the
timulus used, this again was not the case for IL-10 in
he early period after transplantation (Figure 4). The t
B & M Tata for day 14 were analyzed, and there was no
ifference in the IL-10 mRNA levels between the
atients who developed acute GVHD grades II to IV
nd patients who did not develop clinically signiﬁcant
cute GVHD in the unstimulated cultures or in the
ultures stimulated with HLA-mismatched MNCs (P

49 and P 
 .64, respectively; Mann-Whitney test; Fig-
re 4a and b). In contrast, in the cultures stimulated
ith recipient or donor MNCs, the IL-10 mRNA
evels were lower on day 14 in the cultures from
atients who subsequently developed acute GVHD
rades II to IV when compared with cultures from the
atients with acute GVHD grades 0 or I (P
 .005 and

 .004, respectively; Mann-Whitney test; Figure 4c
nd d).
Not only mRNA levels, but also the composition
f the responder cells, varied during the ﬁrst year after
ransplantation. Both the monocyte (CD14) fraction
nd the fraction of CD8 T cells began to deviate
etween the 2 groups of patients after the onset of
cute GVHD, which in most patients occurred be-
ween day 28 and 42 (Figure 4e and f ). The
esponder cell composition was able to inﬂuence the
esults as observed in the pretransplantation setting.
e therefore ﬁnd that the responder cell composition
annot be excluded as a reason for the differences
etween patients with and without acute GVHD that
an be observed from day 28 onward. The differ-
nces appear for TGF- regardless of the stimulus
sed and for IL-10 in the unstimulated cultures and in
he wells containing HLA-mismatched MLC (Figure
a-d). The ﬁnding that peripheral blood MNCs from
atients who subsequently developed acute GVHD
rades II to IV showed lower levels of IL-10 mRNA
n day 14 both in response to irradiated recipient
nd donor cells was surprising, because we would have
xpected a more speciﬁc response. We were therefore
nterested in determining whether the IL-10 mRNA
riginated from the stimulator cells or from responder
ells of donor or recipient origin. The patients were
ot complete hematopoietic chimeras at this time
oint, having a median of 71% donor CD4 T cells
range, 40%-97%) and a median of 64% donor CD8
cells (range, 19%-98%) in the peripheral blood.
he results in the cultures performed before trans-
lantation with unstimulated cells of recipient or do-
or origin were correlated with the results on day14
Figure 5). Whereas a high degree of correlation was
bserved between the recipient cells obtained before
ransplantation and the cultures stimulated with irra-
iated recipient or donor cells on day 14 (Figure 5a
nd b), no correlation was observed between the IL-10
RNA level of the donor cells before transplantation
nd the level in the cultures performed on day 14
Figure 5c and d).
In conclusion, we ﬁnd that the IL-10 mRNA de-
ected on day 14 is more likely to originate from the
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5ecipient responder cells than from the donor re-
ponder cells. The observation that the correlation
ith the pretransplantation recipient values is present
oth in cultures stimulated with recipient and donor
NCs on day 14 makes it unlikely that the IL-10
RNA determined on day 14 originates from the
rradiated stimulator cells. To further study the rela-
ionship between acute GVHD and cells of recipient
nd donor origin, we used the values for CD8 and
D4 T-cell chimerism in each patient to calculate
he numbers of responder recipient and donor T cells
n the cultures performed on day 14. The donor
-cell number did not differ between patients with
nd without acute GVHD (grades 0-I: median, 3300
D8 T cells and 11 400 CD4 T cells; grades II-IV:
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4n contrast, there were signiﬁcantly more recipient
D8 T cells in the cultures with cells from patients
ho did not develop acute GVHD (median, 3600
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ultures from patients who developed acute GVHD
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 .016; Mann-Whitney test). The median
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ultures with cells from patients without development
f acute GVHD (median, 6100 cells; range, 1100-
0 600 cells) when compared with the number in
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 .21; Mann-Whitney test). On day14, data
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5nt stimulator cells and for 12 cultures performed with
onor stimulator cells (Figure 5). Pretransplantation
ata were available in all patients, and when we exam-
ned the relationship between the occurrence of acute
VHD and the pretransplantation level of IL-10, we
ound a trend toward higher levels of IL-10 mRNA in
he unstimulated recipient MNCs from patients who
id not develop clinical signiﬁcant acute GVHD when
ompared to the levels in patients who developed
cute GVHD grades II to IV (Figure 6a). The IL-10
RNA levels of the unstimulated donor MNCs ob-
ained before transplantation showed no difference
ccording to the subsequent occurrence of acute
VHD (Figure 6a). In addition, the patients whose
isease progressed or relapsed had a higher pretrans-
lantation level of IL-10 mRNA in their unstimulated
NCs than the patients whose disease did not progress
Figure 6b). Again, no difference was observed in the
onor cells (Figure 6b). Because of the high incidence
f chronic GVHD in this cohort and the long time
ntervals between the acquirement of blood samples
fter 6 months, we did not attempt to analyze the
elationship between chronic GVHD and cytokine
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6ISCUSSION
In this study, we have investigated whether real-time
T-PCR–based quantiﬁcation of cytokine gene expres-
ion in MNCs obtained from recipients and donors
efore transplantation and from the recipients sequen-
ially after transplantation can contribute to a better
nderstanding of the immune responses underlying
VHD and the GVT effect in patients with hemato-
ogic diseases who undergo transplantation with a
onmyeloablative conditioning regimen. A high de-
ree of correlation between the level of mRNA and
he amount of bioactive cytokine detected in the cul-
ure supernatants was observed for IL-2 and IL-4.
owever, the secretion of IL-10 is regulated by post-
ranscriptional mechanisms [43], and the biological
ctivity of TGF- is also subject to regulation [44],
hus indicating that the amount of bioactive cytokine
ay not be directly estimated from the steady-state
RNA level. Before transplantation the patients had a
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Bponder cells were of donor origin than when recipi-
nt cells were used, the level of IL-2 mRNA per
D4 T cell was not different. We observed a higher
evel of IL-10 mRNA in the unstimulated recipient
NCs when compared with the unstimulated donor
NCs. This may also be due to differences in cell
omposition, because IL-10 is produced by a variety of
ells of the hematopoietic system, including mono-
ytes, T cells, and B cells [45]. In addition, increased
erum levels of IL-10 and increased IL-10 gene expres-
ion have been detected in patients with hematologic
alignancies [46], but whether the IL-10 is produced by
he malignant cells or by other cell populations remains
o be established [45].
In the cultures performed after transplantation, we
lso observed that the cytokine gene expression was
otentially affected by the responder cell composition.
he cell composition of peripheral blood MNCs
hanges dramatically during reconstitution after HCT.
n other studies of cytokine gene expression in MNCs
r buffy coats after HCT, the cell composition was
ot determined [22,24-31]. In one study of in vitro
ytokine production, no differences in cell composi-
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igure 6. Pretransplantation IL-10 mRNA levels, relapse, and
cute GVHD. The relative levels of IL-10 mRNA in unstimulated
ecipient (R) or donor (D) MNCs obtained before transplantation
ere compared on the basis of the occurrence of acute GVHD
rades 0 and I or II to IV (a) and relapse/progression (b). The P
alues of the Mann-Whitney tests are shown.ion were observed between patients with and without a
B & M Thronic GVHD, but in this study all the patients were
xamined 180 days after transplantation, when the
ell composition may be more stable [47]. One way to
vercome the effect of the composition of the MNCs
ould be to study isolated cell populations after HCT,
s has been done by other investigators [34,35,48,49].
e have used different stimuli and have observed that
or IL-10, the stimulation with HLA-identical MNCs
hanges the pattern of gene expression when com-
ared with the unstimulated cells.
We observed higher IL-10 mRNA levels in cul-
ures stimulated with irradiated recipient or donor
ells on day 14 in patients who did not develop
linically signiﬁcant acute GVHD when compared
ith cultures from patients who subsequently devel-
ped acute GVHD grades II to IV. In addition to this,
e found it more likely that the IL-10 mRNA de-
ected on day 14 originated from the recipient frac-
ion of the responder cells than from the donor frac-
ion. It is not clear why the recipient cells should
xpress IL-10 in response to irradiated recipient stim-
lator cells on day 14, but one explanation could be
hat the irradiated recipient cells induce an autoreac-
ive response [50]. We have not included an autol-
gous control in the pretransplantation experiments,
e, recipient MNCs stimulated with irradiated recipi-
nt MNCs and the same for the donor. However, the
ecipient cells express IL-10 in response to all the
timuli used before transplantation (Figure 2d), and in
ur opinion it would therefore be unlikely that the
RNA levels of IL-10 should be low in an autologous
LC with recipient cells, but this issue needs further
lariﬁcation. We also observed more recipient CD8
cells in the cultures performed with cells obtained
n day 14 from patients who did not develop acute
VHD when compared with the cultures with cells
rom patients who developed acute GVHD grades II
o IV. If the IL-10 mRNA detected in this study
riginated from the recipient cells, the observed dif-
erence in IL-10 mRNA levels of patients with and
ithout acute GVHD could in theory be due to dif-
erences in the level of chimerism of T cells or other
ell types. However, another hypothesis could be that
he cytokine milieu early after transplantation could
nﬂuence the rate of development of donor hemato-
oietic chimerism by affecting the alloreactive poten-
ial of the donor cells. The studies of IL-10 levels in
erum or IL-10 gene expression after transplantation
ave come to different results regarding the relation-
hip between IL-10 and acute GVHD. High levels of
L-10 have been associated with tolerance [49] and a
ower incidence of acute GVHD [22,29,31]. However,
ncreased IL-10 levels have also been observed before
r during acute GVHD [14,18-21,26,51]. Because a
ajor biological function of IL-10 is to oppose in-
ammatory responses [45], both the timing of samples
nd the level of inﬂammation induced by the condi-
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5ioning regimen are likely to inﬂuence the results
btained. With the conditioning regimen used in this
tudy, acute GVHD develops rather late after trans-
lantation [36,37], and most patients experience only
inor complications during the ﬁrst 4 weeks after
ransplantation. In this setting, we hypothesize that a
igh level of IL-10 in the recipients may limit the
lloreactive potential of the donor cells, thus leading
o a low incidence of acute GVHD.
We observed high levels of IL-10 mRNA in the
retransplantation samples of patients who experienced
elapse or progression and a trend toward lower levels of
L-10 mRNA in the samples of the patients who devel-
ped acute GVHD grades II to IV. High spontaneous
L-10 production by MNCs before transplantation has
reviously been associated with fewer transplant-related
omplications, including acute GVHD [52,53]. Studies
f gene polymorphisms in the IL-10 promoter region
ave also suggested that recipients who are high IL-10
roducers are protected against severe acute GVHD
54-58] and death in remission [58]. To our knowl-
dge, our data are the ﬁrst to indicate that a high
L-10 gene expression by recipient cells before trans-
lantation is associated with relapse or progression
fter HCT. Most of the previous studies were per-
ormed in recipients of myeloablative conditioning in
atients who were likely to be in remission at the time
f transplantation. In HCT with nonmyeloablative
onditioning, the curative effect relies on the infused
onor cells, and only a minority of the patients are in
omplete remission at the time of transplantation.
actors that tend to reduce the alloreactive potential
f the donor cells may therefore have negative effects
n the control of the malignant disease in these pa-
ients. Because of the high number of comparisons
erformed in this study, we cannot completely exclude
hat the results obtained for IL-10 are accidental ﬁnd-
ngs. However, because alloreactivity is a central ele-
ent of HCT with nonmyeloablative conditioning,
e ﬁnd that our study can contribute to the genera-
ion of hypotheses concerning the regulation of allo-
eactivity in this setting. These hypotheses may then
e tested in larger cohorts of patients.
In conclusion, we ﬁnd that detection of cytokine
ene expression in MNCs by real-time quantitative
T-PCR is an interesting tool in the study of im-
une responses after HCT. Several factors are
ikely to inﬂuence the results obtained, and in this
tudy we have identiﬁed the composition of the
NCs as such a factor. Our results suggest a role
or IL-10 as an inhibitor of alloreactivity after non-
yeloablative HCT. This inhibition may have dual
ffects by limiting the degree of acute GVHD and,
t the same time, increasing the probability of re-
apse.
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